CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
| Business Activity | PASS |
| Debt Ratio | N/A |
| Cash Ratio | N/A |
| Receivables Ratio | N/A |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
$463.8M
2.52
2.172
9
$35.5M
$2.9M
1.33
9.26
0.2%
69
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($12.44, 9 analysts) | |||
| 10 | $38.10 | +$86.30 (227%) | 15.1R |
| 50 | $190.50 | +$431.50 (227%) | 15.1R |
| 100 | $381.00 | +$863.00 (227%) | 15.1R |
- High beta (2.17) — amplifies market moves by 2.17x
- Elevated short interest (9.26 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| ABTC | 0.326 |
| IMTX | 0.317 |
| ASO | 0.308 |
| AMANX | 0.295 |
| ARKG | 0.293 |
| Ticker | Correlation |
|---|---|
| EGRX | -0.235 |
| 2432.T | -0.207 |
| 4519.T | -0.198 |
| AREEC.KW | -0.178 |
| ALEC.AE | -0.175 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.